Australië - Engels - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - dexamethasone, quantity: 0.5 mg/ml; framycetin sulfate, quantity: 5 mg/ml; gramicidin, quantity: 0.05 mg/ml - ear drops - excipient ingredients: phenethyl alcohol; polysorbate 80; citric acid monohydrate; sodium citrate dihydrate; lithium chloride; purified water; industrial methylated spirit; hydrochloric acid; sodium hydroxide - indications as at 5 october 2000: inflammatory and allergic conditions of the ear, e.g. otitis externa. eczema of the auditory meatus is often present and causes inflammation, exudation and pruritus, which are all rapidly relieved by dexamethasone. infection,often secondary to scratching, is generally due to staphylococci, e. coli, pseudomonas and proteus spp. which respond rapidly to framycetin.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - calcium polystyrene sulfonate, quantity: 999.3 mg/g - powder - excipient ingredients: vanillin; saccharin - calcium resonium is an ion-exchange resin. it is recommended for the treatment of hyperkalaemia associated with anuria and severe oliguria.,it is also used to treat hyperkalaemia in patients requiring dialysis and in patients on regular haemodialysis or on prolonged peritoneal dialysis.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - clomifene citrate -

Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

pfizer consumer healthcare div. of pfizer new zealand ltd - paracetamol 24 mg/ml;   - oral suspension - 120mg/5ml - active: paracetamol 24 mg/ml  

Israël - Engels - Ministry of Health

sanofi - aventis israel ltd - buserelin acetate - rods for implant - buserelin acetate 9.9 mg - buserelin - buserelin - treatment of advanced hormone dependent prostatic carcinoma. however not after bilateral orchiectomy ( no further reduction of testosterone level by buserelin to be expected).

Singapore - Engels - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - telithromycin - tablet, film coated - 400 mg

Singapore - Engels - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - hydroxychloroquine sulphate - tablet, film coated - 200 mg - hydroxychloroquine sulphate 200.0 mg

Malta - Engels - Medicines Authority

sanofi malta limited - triamcinolone acetonide - nasal spray, suspension - triamcinolone acetonide 55 microgram(s) - nasal preparations

Europese Unie - Engels - EMA (European Medicines Agency)

sanofi-aventis - rimonabant - obesity - antiobesity preparations, excl. diet products - as an adjunct to diet and exercise for the treatment of obese patients (bmi 30 kg/m2), or overweight patients (bmi 27 kg/m2) with associated risk factor(s), such as type 2 diabetes or dyslipidaemia (see section 5.1).

Europese Unie - Engels - EMA (European Medicines Agency)

aventis pharma s.a. - telithromycin - community-acquired infections; pharyngitis; bronchitis, chronic; pneumonia; tonsillitis; sinusitis - antibacterials for systemic use, - when prescribing levviax consideration should be given to official guidance on the appropriate use of antibacterial agents and the local prevalence of resistance (see also sections 4.4 and 5.1).levviax is indicated for the treatment of the following infections:in patients of 18 years and older:-community-acquired pneumonia, mild or moderate (see section 4.4).- when treating infections caused by known or suspected beta-lactam and/or macrolide resistant strains (according to history of patients or national and/or regional resistance data) covered by the antibacterial spectrum of telithromycin (see sections 4.4 and 5.1):- acute exacerbation of chronic bronchitis,- acute sinusitisin patients of 12 years and older:- tonsillitis/pharyngitis caused by streptococcus pyogenes, as an alternative when beta lactam antibiotics are not appropriate in countries/regions with a significant prevalence of macrolide resistant s. pyogenes, when mediated by ermtr or mefa (see sections 4.4 and 5.1).